Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Jun 20, 2019
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test
Reimbursement Decision Follows IQWiG's Recommendation Based on TAILORx Study Results REDWOOD CITY, Calif. , June 20, 2019 /PRNewswire/ -- Genomic Health announced today that the German Federal Joint Committee (G-BA) issued a positive reimbursement decision for the Oncotype DX Breast Recurrence
Jun 03, 2019
Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
Additional Detail in Patients Age 50 or Younger Presented Today in Oral Session at 2019 American Society of Clinical Oncology ( ASCO ) Annual Meeting TAILORx Continues to Elevate Oncotype DX ® to a New Global Standard with Increasing Utilization and Reimbursement REDWOOD CITY, Calif.
Jun 03, 2019
Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer
New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial to be Presented at ASCO Annual Meeting Today REDWOOD CITY, Calif.
May 29, 2019
Genomic Health to Present at the Jefferies 2019 Healthcare Conference
REDWOOD CITY, Calif. , May 29, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that management will present at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, June 5, 2019 at 2 p.m. Eastern Time . To access the live and subsequently archived webcast
May 07, 2019
Genomic Health Reports First Quarter 2019 Financial Results and Recent Business Progress
Delivered $108.8M in Revenue and Growth of 17.4 Percent Achieved Significant Revenue Growth for All Key Product Areas Reported $13.0M in Profit and EPS of $0.34 Per Share on a Diluted Basis REDWOOD CITY, Calif. , May 7, 2019 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today reported
Apr 30, 2019
Genomic Health to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019
REDWOOD CITY, Calif. , April 30, 2019 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 7 at 4:30 p.m. Eastern Time to discuss its first quarter 2019 financial results.
Mar 25, 2019
New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test
Importance of tailoring chemotherapy use and differences between tests acknowledged by leading international breast cancer specialists REDWOOD CITY, Calif. , March 25, 2019 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St.
Feb 20, 2019
Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance
Delivered $394.1M in Full-year Revenue and Growth of 18 Percent for the Full Year Reported Full-year Profit of $25.7M on a GAAP Basis and $39.7M on a Non-GAAP Basis Achieved 14th Consecutive Quarter of Improved Non-GAAP Profitability Guides to 14% Revenue Growth and 50% Non-GAAP Net Income Growth
Feb 13, 2019
Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019
REDWOOD CITY, Calif. , Feb. 13, 2019 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, February 20 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2018 financial results.
Feb 05, 2019
Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients
Results, Published in Urology, Represent First Prospective Validation of Critical Endpoint to Identify Patients for Active Surveillance REDWOOD CITY, Calif. , Feb. 5, 2019 /PRNewswire/ --  Genomic Health, Inc . (Nasdaq: GHDX) today announced the publication of results from a multi-center,